The combination of Dato-Dxd and immunotherapy is currently being evaluated; TROPION-Lung07 is testing Datopotomab Deruxtecan with Pembrolizumab with or without platinum chemotherapy in patients with previously untreated advanced or metastatic non-squamous NSCLC with PD-L1 expression < 50% and without actionable genomic alterations [42]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.